The ability of purified crystalline preparations obtained from the anterior pituitary to produce growth in hypophysectomized animals has been established repeatedly.3"' The effectiveness of a given preparation can be demonstrated by its ability to produce linear growth" or to produce a positive balance of nitrogen." The production of an increased epiphyseal width is also considered evidence of growth-promoting activity,' although this effect has also been reported as a result of the administration of insulin" or glucagon." In human beings, the production of growth or of epiphyseal changes cannot easily be studied, and most investigations of the effects of the hormone have therefore been confined to balance experiments. Attempts to produce a positive nitrogen balance in normal, diabetic, or hypopituitary human patients have been unsuccessful"""" or incompletely reported."' The difficulties of conducting accurate balance studies in human beings are so great that only relatively large changes can be measured. Consequently, physiologically significant alterations may have been produced in human experiments, but the effect may not have been recognized because of the grossness of the technique. The available preparations of growth hormone have also usually produced untoward effects after several days of administration to human subjects, so that the anabolic actions may have been obscured by the side effects such as fever, nausea, and anorexia.
In addition to its well-established effects in promoting growth, the hormone also produces certain acute alterations in the metabolism which can be detected in relatively short-term experiments in animals. For example, the hormone causes an acute fall of blood glucose in intact rats' and dogs,' a fall of plasma a-amino nitrogen in rats",7",' and in the blood amino nitrogen of cats," and a rise of ketone bodies of rats.""" In hypophysectomized rats, a rise of plasma inorganic phosphate occurs after the administration of growth hormone." Anti-insulin and diabetogenic properties may also manifest themselves after short periods of treatment in animals. 9 7 Since these alterations are probably linked in some way with the growthpromoting effect of the hormone,' and since it seemed likely that the acute changes would be easier to demonstrate in human subjects than long-term changes of nitrogen balance, attempts were made to reproduce in human beings some of the metabolic effects of the acute administration of growth hormone in experimental animals.
METHODS
The subjects consisted of 13 volunteers who were either entirely normal or were convalescing from a minor acute illness. The experiments were conducted after an overnight fast, with the subjects lying at ease on a bed in a quiet room. All venipunctures were made under epinephrine-free procaine local anesthesia. In most cases samples were withdrawn from a Cournand needle set in place in an antecubital vein before the beginning of the experiment so that repeated venipunctures were avoided. No sedatives were used.
The growth hormone* was prepared according to the method of Wilhelmi et al.'7 and was supplied in lyophilized form in sterile bottles containing 25 mg. each. The contents of each bottle were dissolved in five ml. of five per cent sodium bicarbonate in distilled water. In ten cases the dissolved preparation was added to 200 ml. of physiological saline which was injected by slow intravenous drip over a period of 30 or 60 minutes. In three instances, the hormone was diluted to 1,000 or 1,500 ml. and injected over a period of 16 to 24 hours. The solution prepared in this manner was colorless and opalescentanddidnotproduce either subjective or objective reactions in our volunteers, except for mild anorexia after 12 hours of infusion in one case.
In the short-term experiments, blood samples were drawn immediately before the beginning of the injection and as it ended. Additional samples were drawn at hourly intervals up to four hours after the beginning of the experiment. When prolonged infusions were used, samples were drawn immediately before starting the experiment, before each meal, as the injection was completed, and 24 hours after the beginning of the injection. The blood was deproteinated immediately by the appropriate method, and analyses were performed within 36 hours. Glucose was determined by the iodometric titration method of Somogyi,' blood ketones by the method of Greenberg and Lester,' slightly modified, a-amino nitrogen according to the method of Frame and Russell,'"0 and inorganic phosphate by the technique of Fiske and Subbarow."
In some cases attempts were made to show an effect of the growth hormone on the glucose or insulin tolerance tests. These tests were performed 24 hours before and 24 hours after the start of the growth hormone infusion. Insulin tolerance was tested by the intravenous injection of 0.1 unit of crystalline insulin per kilogram of body weight. Glucose tolerance was measured after the intravenous injection of 25 grams of glucose over a period of about one minute. Both tests were followed for about an hour.
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RESULTS
The experimental results of the acute injections are set forth in Tables  1 and 2 . When given over a period of 30 to 60 minutes, one to three mg./kg. of growth hormone failed to affect the concentrations of glucose, a-amino nitrogen, or phosphate in any consistent fashion. The effect of growth hormone on these blood constituents was not different from the effect of saline. Growth hormone consistently caused a rise of the blood ketone body concentration, whereas in the two control subjects where this analysis was performed no change of blood ketones occurred. Observations of hematocrits and plasma proteins during the growth hormone injection showed that no significant hemodilution had occurred. During the course of the prolonged intravenous infusions of growth hormone, there was a consistent rise of blood glucose concentration (Table  3 ). This rise is higher than is seen in normal individuals" (Table 4) . Moreover, in two of the three cases, the postabsorptive blood glucose concentration 24 hours after starting the injection was significantly higher than the pre-injection concentration. Although there was some rise of blood ketone bodies, this was less pronounced than in the subjects who received comparable doses of hormone in a much shorter period. The changes of a-amino nitrogen are difficult to evaluate, since the plasma concentration of this group of substances is reduced by insulin or glucose, and raised by feeding protein, so that any type of change might occur during the course of the day as a result of feeding. The fall of inorganic phosphate probably has a similar explanation.
Following the administration of growth hormone there was no convincing change of the shape of the glucose or insulin tolerance curves, although the fasting levels after the hormone tended to be higher, so that the curves were sometimes parallel rather than superimposed (Fig. 1) . In one case (F.L.) the glucose tolerance appeared to have been somewhat impaired by growth hormone, but this was difficult to interpret, since technical difficulties made it necessary to reduce the amount injected to only 17.5 gm. and to shorten the time of observation. There was no change in the response of inorganic phosphate to insulin or glucose after the administration of growth hormone.
DISCUSSION
Previous attempts to demonstrate an effect of growth hormone in human beings have usually depended on studies of the nitrogen balance carried on over a long period of time. The doses of hormone were frequently rather small, and the preparations were often somewhat toxic. Under these circumstances it is not surprising that most investigators have failed to find any of the anticipated metabolic effects.2 0" 283 In a few cases brief reports have appeared claiming the production of a positive nitrogen balance with various growth preparations, but unfortunately these experiments have not yet been published in sufficient detail to permit evaluation of the data. 8' In two recent studies, however, definite effects of growth hormone in human beings appear to have been well documented. Carballeira, Elrick, and Browne7 showed that the blood amino acid concentration fell faster after the intravenous injection of amino acids if the subjects had received growth hormone. Moreover, less amino acid nitrogen appeared in the urine after growth hormone treatment. These data were interpreted as indicating that growth hormone promoted the storage of amino acids in the tissues. The differences reported are small, but they are consistent and probably significant. These authors also reported a rise of blood glucose and ketone bodies after the injection of growth hormone; however, since they never injected the hormone without also giving amino acids, it is difficult to determine the significance of these changes.
Kinsell et al. '8 have recently reported that the daily intravenous injection of 100 mg. of growth hormone over a 24-hour period for six days in a dia' betic patient on a constant dose of insulin resulted in an increased excretion of glucose in the urine. There was also a rise of ketone bodies, but no consistent change of blood glucose occurred.
The present studies show that the acute intravenous injection of large amounts of the hormone regularly produces ketosis, but has no other detectable effects. When comparable amounts of the hormone are injected slowly over 16 to 24 hours, the production of ketosis is not marked, but a definite increase of blood glucose concentration does occur. This effect does not appear to be reflected in a change of glucose or insulin tolerance.
The pattern of metabolism induced by growth hormone in experimental animals has been well established. Protein is spared from conversion to carbohydrate or fat, or oxidation for energy, and is deposited as new protoplasm.'9 Carbohydrate is likewise spared, both as glycogen,'9 and by virtue of the reduced carbohydrate metabolism, resulting, in its most florid form, in diabetes mellitus.'9" Although the glycogenic effect may be partially antagonized by the release of glucagon, as postulated by Bornstein et al.,' Young,"9 and Foa et al.,"' and the diabetogenic effect combatted by the release of insulin,6"" these adjustments fail to prevent the development of a depressed rate of carbohydrate utilization.'
If protein and carbohydrate become less readily available as energy sources, an increase in fat catabolism must make up the deficit. It is therefore not surprising that growth hormone has been found to cause a mobilization of tissue lipids to the liver'9""' via the blood,5"' presumably as a preliminary to increased fat oxidation. As the breakdown of fat increases, ketosis occurs, probably because the load of two-carbon fragments accumulating in the liver exceeds the capacity of the hepatic enzyme systems to oxidize them directly.
It is of interest that ketosis was produced so easily in our subjects, whereas other changes such as alterations of the plasma a-amino nitrogen, blood glucose, or serum phosphate could not be demonstrated acutely. At least two possible explanations may be considered for this discrepancy. The dose may have been too small to produce the nitrogen or carbohydrate effects, or the time of observation may have been too short to permit them to appear. In dogs, ketosis and hyperlipemia occur within a few hours after the administration of the hormone, whereas insulin or glucose tolerance alterations require a much longer period of treatment.'m Perhaps the same is true of man. In either case, whether because of too little hormone or too little time, it is difficult to escape the conclusion that the shift to a high-fat metabolic pattern is the earliest observed change produced by the hormone. If this is the case, the emphasis on carbohydrate and protein in the preceding discussion may have been incorrect. Instead of considering the ketosis a result of changes of protein and carbohydrate metabolism, it might be more nearly correct to view the shift to a high-fat metabolic substrate as the basic alteration which precedes and facilitates the more spectacular protein and carbohydrate effects. The observations of Greenbaum' that the hormone-induced growth ceases when body fat depots are exhausted supports this viewpoint.
This interpretation is apparently in conflict with the observations that the lipid-mobilizing ("adipokinetic") action of pituitary extracts is not necessarily associated with the growth hormone fraction.28' "' It is possible, however, that the fat-mobilizing activity of the pituitary may reside in several different fractions. In any case, it is difficult to see how a material with the metabolic properties ascribed to the purified preparations of growth hormone now available could fail to exert a fat-catabolism-promoting effect.
SUMMARY
The intravenous injection of purified crystalline growth hormone in doses of one to five mg./kg. over periods of 30 minutes to 24 hours failed to alter the plasma amino acid concentration, the serum phosphate, or the insulin or glucose tolerance of normal human volunteers. When the hormone was given rapidly, ketosis developed, but when it was given slowly the ketogenic effect was less marked and a rise of blood glucose occurred.
Since ketosis appeared earlier and more consistently than any other change, and since alterations of fat metabolism occur in animals before changes in carbohydrate or protein metabolism can be demonstrated, it is suggested that the basic effect of growth hormone may be to promote the use of fat as the major metabolic substrate. This would reduce the demand for protein and carbohydrate as sources of energy and facilitate their storage as protoplasm and glycogen, respectively. ACKNOWLEDGMENT Doctors R. 0. Burgess and Lawrence R. Freedman generously gave of their time to make this study possible.
